Cargando…

P19-39. Vaccibodies: a novel vaccine strategy for HIV that target viral antigens to APC

Detalles Bibliográficos
Autores principales:	Øynebråten, I, Fredriksen, A, Barouch, D, Bogen, B
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2767869/ http://dx.doi.org/10.1186/1742-4690-6-S3-P359

Ejemplares similares

Increased Generation of HIV-1 gp120-Reactive CD8(+) T Cells by a DNA Vaccine Construct Encoding the Chemokine CCL3
por: Øynebråten, Inger, et al.
Publicado: (2014)

The Specificity of Targeted Vaccines for APC Surface Molecules Influences the Immune Response Phenotype
por: Grødeland, Gunnveig, et al.
Publicado: (2013)

Multivalent adenoviral vectors which use an antigen capsid-incorporation strategy for HIV vaccination
por: Gu, L, et al.
Publicado: (2012)

Engineered microneedle arrays for transcutaneous HIV vaccine delivery
por: DeMuth, P, et al.
Publicado: (2012)

Coupling of HIV-1 Antigen to the Selective Autophagy Receptor SQSTM1/p62 Promotes T-Cell-Mediated Immunity
por: Andersen, Aram Nikolai, et al.
Publicado: (2016)

P11-03. Mucosal trafficking and differentiation of vaccine-elicited CD8+ T-lymphocytes
por: Kaufman, DR, et al.
Publicado: (2009)

P15-23. Community engagement strategies in the Canadian HIV vaccine initiative
por: Milsom, P, et al.
Publicado: (2009)

Gag-specific cellular immunity determines in vitro viral inhibition and in vivo virologic control following SIV challenges of vaccinated monkeys
por: Stephenson, KE, et al.
Publicado: (2012)

Preliminary report of a clinical trial supporting the sequential use of an attenuated E39 peptide (E39') to optimize the immunologic response to the FBP (E39+GM-CSF) vaccine
por: Jackson, Doreen, et al.
Publicado: (2015)

P16-39. T cell recognition of autologous and non-autologous HIV-1 protease peptides by HIV-1 infected patients undergoing PI therapy
por: Moraes, SL, et al.
Publicado: (2009)

P19-45. Development of a therapeutic HIV vaccine comprised of autologous dendritic cells loaded with a mixture of lipopeptide HIV antigens
por: Cobb, AJ, et al.
Publicado: (2009)

Live, attenuated rubella vectors expressing HIV and SIV vaccine antigens
por: Berkower, I, et al.
Publicado: (2012)

P17-16. Anti-Langerin-HIV Gag p24 fusion protein targeting Langerhans cells as a new anti-HIV vaccine strategy
por: Culina, S, et al.
Publicado: (2009)

Genetically modified artificial antigen-presenting cells (aAPC) for expansion of melanoma tumor infiltrating lymphocytes with optimal properties for adoptive cell therapy
por: Forget, Marie-Andrée, et al.
Publicado: (2013)

P18-10. Ability of HIV antigens-pulsed monocyte-derived dendritic cells to induce HIV-specific T cell response: potential use in therapeutic vaccine
por: Silveira, GG, et al.
Publicado: (2009)

APC is epigenetically down regulated in advance cases of gallbladder cancer
por: Singh, Dinesh Tekcham, et al.
Publicado: (2014)

P04.39. Leadership and education program for students in integrative medicine: LEAPS into IM
por: Guerrera, M, et al.
Publicado: (2012)

P01.39. Synergism of herbs in classical Chinese medicine: evidence from HPLC
por: Shaw, K, et al.
Publicado: (2012)

Polarizing T and B Cell Responses by APC-Targeted Subunit Vaccines
por: Grødeland, Gunnveig, et al.
Publicado: (2015)

Development of replication-competent adenovirus based vaccine vectors
por: Abbink, P, et al.
Publicado: (2012)

P17-22. Impact of rare adenovirus seroprevalence on HIV-1 acquisition in the Step study
por: Maxfield, LF, et al.
Publicado: (2009)

Role of HC-gp39 in chondrogenesis: upregulation of SOX-9 expression by HC-gp39 in mouse chondrocytes
por: Jacques, C, et al.
Publicado: (2003)

P02-02. Analysis of antigen specific degranulation potentials using IL-12 or IL-28B during HIV DNA Vaccination
por: Morrow, M, et al.
Publicado: (2009)

P02.39. Leveraging grant awards to enhance the research infrastructure at a CAM institution
por: Pohlman, K, et al.
Publicado: (2012)

Novel strategies for HIV-1 epitope delivery using foamy viral hybrid proteins and vectors
por: Mühle, M, et al.
Publicado: (2012)

Detection of HIV-1 antigen associated to erythrocytes in patients with undetectable viral load in plasma for more than one year
por: Garcia, María Noé, et al.
Publicado: (2006)

HIV-1 capture and antigen presentation by dendritic cells: enhanced viral capture does not correlate with better T-Cell activation
por: Rodriguez-Plata, M, et al.
Publicado: (2012)

Adjuvant inhibition of iAPC function in the tumor microenvironment promotes therapeutic immunity in the setting of vaccination-induced T cell anti-tumor response
por: Antonios, Joseph, et al.
Publicado: (2015)

P56. A novel cancer vaccine with nanogel-based antigen transporter and sequence-optimised long peptide antigen
por: Harada, N, et al.
Publicado: (2014)

P16-23. Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance
por: Tenzer, S, et al.
Publicado: (2009)

P15-06. Brighton collaboration viral vector vaccines safety working group (V3SWG): maximizing the comparability and value of safety data from HIV vaccine trials
por: Chen, RT, et al.
Publicado: (2009)

Human leukocyte antigen class I supertypes and viral control in HIV-1 infected former plasma donors from China
por: Hao, J, et al.
Publicado: (2012)

P20-06. Study of viral variability evolution in patients submitted to a therapeutic vaccine based on autologous dendritic cells pulsed with autologous HIV-1
por: Guilà, M, et al.
Publicado: (2009)

P16-27.Optimization of the expansion of antigen-specific CD8+ T-cells for use in a viral suppression assay
por: Herman, MM, et al.
Publicado: (2009)

P09-10. Impact of CTL escape mutations in HIV-1 Nef on viral replication
por: Oniangue-Ndza, C, et al.
Publicado: (2009)

Vaccination with dendritic cells loaded with HIV-1 lipopeptides elicits broad T cell immunity and control of viral load in HIV infected patients
por: Levy, Y, et al.
Publicado: (2012)

Generation of Antibody-Producing Hybridomas Following One Single Immunization with a Targeted DNA Vaccine
por: Øynebråten, I, et al.
Publicado: (2012)

From HIV protein sequences to viral fitness landscapes: a new paradigm for in silico vaccine design
por: Ferguson, AL, et al.
Publicado: (2012)

P39 Cross sectional survey of medical student volunteering and education during the coronavirus pandemic in the United Kingdom
por: Byrne, Matthew H V, et al.
Publicado: (2021)

P17-23. Enhanced expression of HIV antigens and improved antigen presentation after infection with replication competent attenuated vaccinia virus in vitro
por: Quakkelaar, E, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_5qgp9pst1s23u4hrf5qpg33bp7